Jacobsen et al. reported a case of RDD with KRAS mutation successfully treated with cobimetinib, a MEK inhibitor, which provided further support of the importance of the MAPK/ERK pathway in RDD [33]. This evidence concerns the gene KRAS and sinus histiocytosis with massive lymphadenopathy.